News Center

Welcome to the Janssen News Center. Here you’ll find our latest press releases, corporate statements, and additional resources.

Press Releases

11/04/2011

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

09/14/2011

New Survey Shows Moderate-to-Severe Acute Pain is Widely Undertreated, Especially Among Older Adults

08/26/2011

NUCYNTA® ER (tapentadol extended-release tablets) Receives FDA Approval for the Management of Moderate to Severe Chronic Pain

08/16/2011

Janssen Pharmaceuticals, Inc. Launches Online Tools on PrescribeResponsibly.com

08/02/2011

The Current and Future Practice of Psychiatric Nursing

07/01/2011

FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery

06/17/2011

Ortho-McNeil-Janssen Pharmaceuticals, Inc. is initiating a voluntary recall of one lot of RISPERDAL® (risperidone) 3mg Tablets, marketed by Janssen Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and one lot of risperidone 2mg Tablets, marketed by Patriot Pharmaceuticals, LLC, a wholly owned subsidiary of Ortho-McNeil-Janssen Pharmaceuticals, Inc. 

05/09/2011
“Living with Schizophrenia” Documentary Shines Spotlight on People with Schizophrenia: A Misunderstood and Stigmatized Illness
04/14/2011

Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. is initiating a voluntary recall of two lots of TOPAMAX® 100mg tablets. Click here to see Company press release. Click here for Urgent Drug Product Recall letter sent to whol

04/11/2011
INVEGA® Approved as Treatment for Schizophrenia in Adolescents

Corporate Statements

There are no statements at this time.

Additional Resources

Click here for virtual press kits.